AstraZeneca PLC (AZN) EV/FCF Ratio: 34.13x
Is AstraZeneca PLC’s EV/FCF ratio high or low?
AstraZeneca PLC's EV/FCF ratio of 34.13x is in line with its 5-year average of 36.94x, near the low end of its 5-year range (23.53x–61.39x).
As of Friday, June 12, 2026. 13.42% above its 12-month average of 30.09x.
AZN EV/FCF Ratio Chart
AZN Average EV/FCF Ratio Chart
AZN Current vs Average EV/FCF Ratio Chart
AZN EV/FCF Ratio Metrics
EV/FCF RATIO
34.13x
EV/FCF RATIO AVG TTM
30.09x
EV/FCF RATIO AVG 3Y
33.92x
EV/FCF RATIO AVG 5Y
36.94x
EV/FCF RATIO AVG 10Y
66.52x
EV/FCF RATIO AVG 15Y
52.54x
EV/FCF RATIO AVG 20Y
42.20x
CURRENT VS TTM AVG
+13.42%
CURRENT VS 3Y AVG
+0.61%
CURRENT VS 5Y AVG
-7.61%
CURRENT VS 10Y AVG
-48.69%
CURRENT VS 15Y AVG
-35.04%
CURRENT VS 20Y AVG
-19.12%
AZN Competitors' EV/FCF Ratio
| NAME | MARKET CAP | EV/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| AstraZeneca PLC (AZN) | $282.69B | 34.13x | 30.09x | 33.92x | 36.94x |
| Merck & Co., Inc. (MRK) | $298.29B | 24.25x | 20.30x | 23.16x | 23.70x |
| UnitedHealth Group Incorporated (UNH) | $368.30B | 21.30x | 17.62x | 29.11x | 26.10x |
| Amgen Inc. (AMGN) | $191.09B | 27.67x | 22.37x | 24.94x | 22.50x |
| Thermo Fisher Scientific Inc. (TMO) | $176.77B | 32.21x | 35.74x | 34.61x | 34.76x |
| AbbVie Inc. (ABBV) | $397.12B | 22.15x | 23.69x | 20.02x | 17.82x |
| Gilead Sciences, Inc. (GILD) | $156.28B | 16.85x | 18.52x | 16.04x | 14.51x |
| Abbott Laboratories (ABT) | $156.15B | 24.92x | 30.96x | 34.90x | 31.02x |
| Pfizer Inc. (PFE) | $149.18B | 22.43x | 19.77x | 27.32x | 21.37x |
| Intuitive Surgical, Inc. (ISRG) | $146.23B | 51.70x | 79.55x | 160.31x | 125.13x |
Cash Flow Valuation Comparison
EV/FCF
34.1x
P/FCF
31.2x
FCF Yield
3.20%
Formula: EV/FCF = Enterprise Value / Free Cash Flow
EV/FCF vs P/FCF:
- EV/FCF accounts for debt and cash through enterprise value
- P/FCF only considers equity value
- EV/FCF can be compared across companies with different debt levels
- Both measure how the market values cash generation
AstraZeneca PLC EV/FCF Ratio Formula & Definition
EV/FCF = Enterprise Value / Free Cash Flow (TTM)
Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
AstraZeneca PLC EV/FCF Ratio FAQ
- What is the EV/FCF ratio for AstraZeneca PLC (AZN)?
- The EV/FCF ratio for AZN stock is 34.13x.
- Is AstraZeneca PLC's EV/FCF ratio high or low?
- AstraZeneca PLC's EV/FCF ratio of 34.13x is in line with its 5-year average of 36.94x, near the low end of its 5-year range (23.53x–61.39x).
- What is the TTM average EV/FCF ratio for AstraZeneca PLC (AZN)?
- The TTM average EV/FCF ratio for AZN stock is 30.09x.
- What is the 3Y average EV/FCF ratio for AstraZeneca PLC (AZN)?
- The 3Y average EV/FCF ratio for AZN stock is 33.92x.
- What is the 5Y average EV/FCF ratio for AstraZeneca PLC (AZN)?
- The 5Y average EV/FCF ratio for AZN stock is 36.94x.
- What is the 10Y average EV/FCF ratio for AstraZeneca PLC (AZN)?
- The 10Y average EV/FCF ratio for AZN stock is 66.52x.
- What is the 15Y average EV/FCF ratio for AstraZeneca PLC (AZN)?
- The 15Y average EV/FCF ratio for AZN stock is 52.54x.
- What is the 20Y average EV/FCF ratio for AstraZeneca PLC (AZN)?
- The 20Y average EV/FCF ratio for AZN stock is 42.20x.
AstraZeneca PLC EV/FCF Ratio History
| DATE | EV/FCF RATIO |
|---|---|
| 2026-06-11 | 34.13x |
| 2026-06-10 | 33.56x |
| 2026-06-09 | 34.33x |
| 2026-06-08 | 34.01x |
| 2026-06-05 | 34.76x |
| 2026-06-04 | 34.05x |
| 2026-06-03 | 33.10x |
| 2026-06-02 | 33.30x |
| 2026-06-01 | 33.69x |
| 2026-05-29 | 34.71x |
| 2026-05-28 | 34.66x |
| 2026-05-27 | 34.71x |
| 2026-05-26 | 34.97x |
| 2026-05-22 | 34.95x |
| 2026-05-21 | 35.41x |
| 2026-05-20 | 35.02x |
| 2026-05-19 | 34.54x |
| 2026-05-18 | 34.41x |
| 2026-05-15 | 34.01x |
| 2026-05-14 | 34.59x |
| 2026-05-13 | 35.06x |
| 2026-05-12 | 34.52x |
| 2026-05-11 | 34.06x |
| 2026-05-08 | 34.23x |
| 2026-05-07 | 34.17x |
| 2026-05-06 | 34.59x |
| 2026-05-05 | 33.95x |
| 2026-05-04 | 34.33x |
| 2026-05-01 | 34.55x |
| 2026-04-30 | 35.00x |
| 2026-04-29 | 34.63x |
| 2026-04-28 | 29.85x |
| 2026-04-27 | 29.98x |
| 2026-04-24 | 30.31x |
| 2026-04-23 | 30.68x |
| 2026-04-22 | 31.05x |
| 2026-04-21 | 31.20x |
| 2026-04-20 | 31.92x |
| 2026-04-17 | 32.53x |
| 2026-04-16 | 31.89x |
| 2026-04-15 | 32.00x |
| 2026-04-14 | 32.47x |
| 2026-04-13 | 32.15x |
| 2026-04-10 | 32.42x |
| 2026-04-09 | 32.56x |
| 2026-04-08 | 32.45x |
| 2026-04-07 | 31.94x |
| 2026-04-06 | 32.24x |
| 2026-04-02 | 32.34x |
| 2026-04-01 | 31.93x |
| 2026-03-31 | 31.41x |
| 2026-03-30 | 30.92x |
| 2026-03-27 | 30.11x |
| 2026-03-26 | 29.37x |
| 2026-03-25 | 29.92x |
| 2026-03-24 | 29.72x |
| 2026-03-23 | 29.47x |
| 2026-03-20 | 29.40x |
| 2026-03-19 | 30.18x |
| 2026-03-18 | 30.11x |
| 2026-03-17 | 30.53x |
| 2026-03-16 | 30.64x |
| 2026-03-13 | 30.33x |
| 2026-03-12 | 30.71x |
| 2026-03-11 | 30.83x |
| 2026-03-10 | 31.08x |
| 2026-03-09 | 31.07x |
| 2026-03-06 | 30.97x |
| 2026-03-05 | 31.45x |
| 2026-03-04 | 32.05x |
| 2026-03-03 | 32.08x |
| 2026-03-02 | 32.37x |
| 2026-02-27 | 33.07x |
| 2026-02-26 | 32.41x |
| 2026-02-25 | 32.68x |
| 2026-02-24 | 32.80x |
| 2026-02-23 | 30.90x |
| 2026-02-20 | 30.80x |
| 2026-02-19 | 31.41x |
| 2026-02-18 | 31.42x |
| 2026-02-17 | 31.53x |
| 2026-02-13 | 30.98x |
| 2026-02-12 | 30.84x |
| 2026-02-11 | 30.87x |
| 2026-02-10 | 29.24x |
| 2026-02-09 | 28.53x |
| 2026-02-06 | 29.23x |
| 2026-02-05 | 28.41x |
| 2026-02-04 | 28.45x |
| 2026-02-03 | 28.01x |
| 2026-02-02 | 28.58x |
| 2026-01-30 | 28.40x |
| 2026-01-29 | 27.85x |
| 2026-01-28 | 28.50x |
| 2026-01-27 | 28.54x |
| 2026-01-26 | 27.27x |
| 2026-01-23 | 27.06x |
| 2026-01-22 | 27.34x |
| 2026-01-21 | 26.71x |
| 2026-01-20 | 27.85x |
| 2026-01-16 | 28.96x |
| 2026-01-15 | 28.64x |
| 2026-01-14 | 28.84x |
| 2026-01-13 | 28.62x |
| 2026-01-12 | 28.17x |
| 2026-01-09 | 28.95x |
| 2026-01-08 | 28.60x |
| 2026-01-07 | 28.92x |
| 2026-01-06 | 28.88x |
| 2026-01-05 | 27.27x |
| 2026-01-02 | 27.78x |
| 2025-12-31 | 26.78x |
| 2025-12-30 | 27.53x |
| 2025-12-29 | 28.39x |
| 2025-12-26 | 27.59x |
| 2025-12-24 | 28.30x |
| 2025-12-23 | 27.83x |
| 2025-12-22 | 27.51x |
| 2025-12-19 | 27.58x |
| 2025-12-18 | 27.48x |
| 2025-12-17 | 28.07x |
| 2025-12-16 | 27.78x |
| 2025-12-15 | 27.95x |
| 2025-12-12 | 27.36x |
| 2025-12-11 | 27.49x |
| 2025-12-10 | 27.68x |
| 2025-12-09 | 27.28x |
| 2025-12-08 | 27.54x |
| 2025-12-05 | 27.33x |
| 2025-12-04 | 27.41x |
| 2025-12-03 | 27.87x |
| 2025-12-02 | 27.28x |
| 2025-12-01 | 27.46x |
| 2025-11-28 | 27.93x |
| 2025-11-26 | 28.60x |
| 2025-11-25 | 28.49x |
| 2025-11-24 | 27.78x |
| 2025-11-21 | 27.77x |
| 2025-11-20 | 27.11x |
| 2025-11-19 | 27.38x |
| 2025-11-18 | 26.73x |
| 2025-11-17 | 26.74x |
| 2025-11-14 | 26.68x |
| 2025-11-13 | 27.06x |
| 2025-11-12 | 26.80x |
| 2025-11-11 | 26.73x |
| 2025-11-10 | 26.69x |
| 2025-11-07 | 25.47x |
| 2025-11-06 | 25.87x |
| 2025-11-05 | 31.96x |
| 2025-11-04 | 32.49x |
| 2025-11-03 | 31.89x |
| 2025-10-31 | 32.41x |
| 2025-10-30 | 32.38x |
| 2025-10-29 | 32.21x |
| 2025-10-28 | 32.54x |
| 2025-10-27 | 32.26x |
| 2025-10-24 | 32.22x |
| 2025-10-23 | 33.02x |
| 2025-10-22 | 32.77x |
| 2025-10-21 | 33.03x |
| 2025-10-20 | 32.79x |
| 2025-10-17 | 33.49x |
| 2025-10-16 | 33.18x |
| 2025-10-15 | 32.99x |
| 2025-10-14 | 33.17x |
| 2025-10-13 | 33.16x |
| 2025-10-10 | 33.22x |
| 2025-10-09 | 33.31x |
| 2025-10-08 | 33.71x |
| 2025-10-07 | 33.33x |
| 2025-10-06 | 33.75x |
| 2025-10-03 | 33.43x |
| 2025-10-02 | 32.38x |
| 2025-10-01 | 32.01x |
| 2025-09-30 | 29.67x |
| 2025-09-29 | 29.06x |
| 2025-09-26 | 29.07x |
| 2025-09-25 | 29.72x |
| 2025-09-24 | 29.59x |
| 2025-09-23 | 29.89x |
| 2025-09-22 | 30.98x |
| 2025-09-19 | 30.54x |
| 2025-09-18 | 30.37x |
| 2025-09-17 | 30.84x |
| 2025-09-16 | 30.30x |
| 2025-09-15 | 30.58x |
| 2025-09-12 | 31.47x |
| 2025-09-11 | 31.90x |
| 2025-09-10 | 31.57x |
| 2025-09-09 | 31.64x |
| 2025-09-08 | 32.11x |
| 2025-09-05 | 32.35x |
| 2025-09-04 | 31.90x |
| 2025-09-03 | 31.95x |
| 2025-09-02 | 31.67x |
| 2025-08-29 | 31.75x |
| 2025-08-28 | 31.23x |
| 2025-08-27 | 31.66x |
| 2025-08-26 | 31.60x |
| 2025-08-25 | 32.08x |
| 2025-08-22 | 31.03x |
| 2025-08-21 | 31.71x |
| 2025-08-20 | 31.15x |
| 2025-08-19 | 31.38x |
| 2025-08-18 | 31.63x |
| 2025-08-15 | 30.74x |
| 2025-08-14 | 30.79x |
| 2025-08-13 | 30.53x |
| 2025-08-12 | 29.45x |
| 2025-08-11 | 29.07x |
| 2025-08-08 | 28.29x |
| 2025-08-07 | 29.27x |
| 2025-08-06 | 29.52x |
| 2025-08-05 | 29.81x |
| 2025-08-04 | 29.82x |
| 2025-08-01 | 29.31x |
| 2025-07-31 | 29.29x |
| 2025-07-30 | 30.77x |
| 2025-07-29 | 29.85x |
| 2025-07-28 | 25.98x |
| 2025-07-25 | 26.18x |
| 2025-07-24 | 26.43x |
| 2025-07-23 | 26.50x |
| 2025-07-22 | 25.62x |
| 2025-07-21 | 25.27x |
| 2025-07-18 | 24.93x |
| 2025-07-17 | 25.08x |
| 2025-07-16 | 25.64x |
| 2025-07-15 | 25.38x |
| 2025-07-14 | 25.83x |
| 2025-07-11 | 25.36x |
| 2025-07-10 | 25.90x |
| 2025-07-09 | 25.54x |
| 2025-07-08 | 25.34x |
| 2025-07-07 | 25.74x |
| 2025-07-03 | 25.43x |
| 2025-07-02 | 25.94x |
| 2025-07-01 | 25.27x |
| 2025-06-30 | 25.28x |
| 2025-06-27 | 25.02x |
| 2025-06-26 | 25.31x |
| 2025-06-25 | 26.32x |
| 2025-06-24 | 25.49x |
| 2025-06-23 | 25.64x |
| 2025-06-20 | 25.27x |
| 2025-06-18 | 25.90x |
| 2025-06-17 | 25.47x |
| 2025-06-16 | 26.66x |
| 2025-06-13 | 26.61x |
| 2025-06-12 | 26.95x |
| 2025-06-11 | 26.64x |
| 2025-06-10 | 26.39x |
| 2025-06-09 | 26.37x |
| 2025-06-06 | 26.01x |
| 2025-06-05 | 25.76x |
| 2025-06-04 | 26.23x |
| 2025-06-03 | 25.72x |
| 2025-06-02 | 25.72x |
| 2025-05-30 | 25.56x |
Showing the most recent 260 of 4,927 data points. The chart above shows the full history.
Related Metrics
About AstraZeneca PLC
AstraZeneca PLC operates as a global biopharmaceutical leader, dedicated to the entire process of bringing prescription medicines to market, from their initial discovery and development through manufacturing and commercialization. The company's extensive portfolio of treatments, including prominent examples like Tagrisso, Farxiga, and Symbicort, addresses critical areas such as cardiovascular, renal, metabolic, and oncological conditions. Furthermore, it provides essential solutions for COVID-19 and various rare diseases, with products like Vaxzevria and Soliris. AstraZeneca engages with primary and specialty care physicians worldwide, facilitating distribution through a robust network of representatives and local offices across the United Kingdom, continental Europe, the Americas, Asia, Africa, and Australasia. The firm actively drives innovation through strategic collaborations, partnering with entities such as Neurimmune AG for the development and commercialization of NI006, BenevolentAI for systemic lupus erythematosus drug discovery, Lunit for AI-powered digital pathology risk assessment in NSCLC, and Absci Corporation for AI-driven oncology target identification. Founded in 1992, the company was initially known as Zeneca Group PLC, subsequently rebranding to AstraZeneca PLC in April 1999, and maintains its headquarters in Cambridge, United Kingdom.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Pascal Claude Roland Soriot